ATE419537T1 - Verwendung eines polypeptids zur auffindung von multipler sklerose - Google Patents

Verwendung eines polypeptids zur auffindung von multipler sklerose

Info

Publication number: ATE419537T1
Authority: AT; Austria
Prior art keywords: detecting; degenerative; neurological; treating; polypeptide
Prior art date: 1999-07-15

Application number

AT00953247T

Other languages

English (en)

Inventor

Dominique Roecklin

Hanno Kolbe

Marie-Helene Charles

Carine Malcus

Lyse Santoro

Herve Perron

Original Assignee

Biomerieux Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-15

Filing date

2000-07-17

Publication date

2009-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9548286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419537(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-07-17 Application filed by Biomerieux Sa filed Critical Biomerieux Sa

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE419537T1 publication Critical patent/ATE419537T1/de

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
229920001184 polypeptide Polymers 0.000 title abstract 3
201000006417 multiple sclerosis Diseases 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 3
208000012902 Nervous system disease Diseases 0.000 abstract 3
208000025966 Neurological disease Diseases 0.000 abstract 3
230000003412 degenerative effect Effects 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
208000015122 neurodegenerative disease Diseases 0.000 abstract 3
230000000926 neurological effect Effects 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
102000004169 proteins and genes Human genes 0.000 abstract 3
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
239000002243 precursor Substances 0.000 abstract 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract 1
102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 abstract 1
102000004506 Blood Proteins Human genes 0.000 abstract 1
108010017384 Blood Proteins Proteins 0.000 abstract 1
102000018755 Calgranulin B Human genes 0.000 abstract 1
108010052495 Calgranulin B Proteins 0.000 abstract 1
102100023364 Ganglioside GM2 activator Human genes 0.000 abstract 1
101710201362 Ganglioside GM2 activator Proteins 0.000 abstract 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
102000017852 Saposin Human genes 0.000 abstract 1
108050007079 Saposin Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 abstract 1
238000001415 gene therapy Methods 0.000 abstract 1
230000002519 immonomodulatory effect Effects 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
CKAXXGPMLYVWQI-UHFFFAOYSA-N lycorin Chemical compound C1C2=CC=3OCOC=3C=C2C2C(O)C(O)=CC3C2N1CC3 CKAXXGPMLYVWQI-UHFFFAOYSA-N 0.000 abstract 1
238000004949 mass spectrometry Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000035772 mutation Effects 0.000 abstract 1
108010049224 perlecan Proteins 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960003471 retinol Drugs 0.000 abstract 1
235000020944 retinol Nutrition 0.000 abstract 1
239000011607 retinol Substances 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Rehabilitation Therapy (AREA)

AT00953247T 1999-07-15 2000-07-17 Verwendung eines polypeptids zur auffindung von multipler sklerose ATE419537T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9909372A FR2797402B1 (fr)	1999-07-15	1999-07-15	Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune

Publications (1)

Publication Number	Publication Date
ATE419537T1 true ATE419537T1 (de)	2009-01-15

Family

ID=9548286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00953247T ATE419537T1 (de)	1999-07-15	2000-07-17	Verwendung eines polypeptids zur auffindung von multipler sklerose

Country Status (10)

Country	Link
US (2)	US7081345B1 (de)
EP (2)	EP2081028A1 (de)
JP (1)	JP2003509340A (de)
AT (1)	ATE419537T1 (de)
AU (1)	AU6576800A (de)
CA (1)	CA2379336A1 (de)
DE (1)	DE60041265D1 (de)
ES (1)	ES2317845T3 (de)
FR (1)	FR2797402B1 (de)
WO (1)	WO2001005422A2 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6902890B1 (en)	1999-11-04	2005-06-07	Diadexus, Inc.	Method of diagnosing monitoring, staging, imaging and treating cancer
AU2001233715A1 (en) *	2000-01-26	2001-08-07	Memorec Medical Molecular Research Cologne Stoffel Gmbh	Dermo- and gastro-specific sphingolipid activator
AU2001286791A1 (en) *	2000-08-31	2002-03-13	University Of Delaware	Bioactive peptide for cell adhesion
CA2434677A1 (en) *	2001-01-12	2002-10-10	Incyte Genomics, Inc.	Molecules for diagnostics and therapeutics
US20030040602A1 (en) *	2001-04-30	2003-02-27	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons
US6627608B2 (en)	2001-04-30	2003-09-30	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
US6998243B2 (en)	2001-04-30	2006-02-14	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US20020160418A1 (en) *	2001-04-30	2002-10-31	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1949 daltons
US20040224423A1 (en) *	2001-04-30	2004-11-11	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
US20020160421A1 (en) *	2001-04-30	2002-10-31	George Jackowski	Method for monitoring and validating stress induction of disease state
US6620787B2 (en)	2001-04-30	2003-09-16	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
US6703366B2 (en) *	2001-04-30	2004-03-09	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltons
US6756476B2 (en)	2001-04-30	2004-06-29	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US6627606B2 (en) *	2001-04-30	2003-09-30	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
US6593298B2 (en) *	2001-04-30	2003-07-15	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
US20020160417A1 (en) *	2001-04-30	2002-10-31	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
US6602855B2 (en) *	2001-04-30	2003-08-05	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
US20040198950A1 (en) *	2001-04-30	2004-10-07	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
US6620786B2 (en) *	2001-04-30	2003-09-16	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having molecular weight of 2937 daltons
US6677303B2 (en) *	2001-04-30	2004-01-13	Syn X Pharma	Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
US7008800B2 (en)	2001-04-30	2006-03-07	Artemis Proteomics, Ltd.	Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
US20020160423A1 (en) *	2001-04-30	2002-10-31	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1536 daltons
US7314717B2 (en)	2001-04-30	2008-01-01	Nanogen Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US20020160532A1 (en) *	2001-04-30	2002-10-31	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons
US20020160533A1 (en)	2001-04-30	2002-10-31	George Jackowski	Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons
US7049397B2 (en) *	2001-04-30	2006-05-23	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
US6693080B2 (en) *	2001-04-30	2004-02-17	Syn X Pharma	Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons
US20020160434A1 (en) *	2001-04-30	2002-10-31	George Jackowski	Biopolymer marker indicative of disease state having a molecular weight of 1777 daltons
US6599877B2 (en)	2001-04-30	2003-07-29	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
US7294688B2 (en) *	2001-04-30	2007-11-13	Nanogen Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6890763B2 (en) *	2001-04-30	2005-05-10	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
US6627607B2 (en)	2001-04-30	2003-09-30	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
US6617308B2 (en) *	2001-04-30	2003-09-09	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7087435B2 (en) *	2001-04-30	2006-08-08	Syn X Pharma, Inc.	Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
GB0112626D0 (en)	2001-05-23	2001-07-18	Osteometer Biotech As	Assay of isomerised and/or optically inverted proteins and protein fragments
US20030100012A1 (en) *	2001-11-23	2003-05-29	George Jackowski	Plasma protease C1 biopolymer markers predictive of alzheimers disease
AU2002336842A1 (en) *	2001-11-23	2003-06-10	Syn.X Pharma, Inc.	Hp and apolipoprotein biopolymer markers predictive of alzheimers disease
WO2003046566A2 (en) *	2001-11-23	2003-06-05	Syn.X Pharma, Inc.	Pedf biopolymer markers predictive of alzheimers disease
US7179606B2 (en) *	2001-11-23	2007-02-20	Syn X Pharma, Inc.	IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
US20030100016A1 (en) *	2001-11-23	2003-05-29	George Jackowski	Complement C3 precursor biopolymer markers predictive of Alzheimers disease
US20070003974A1 (en) *	2001-11-23	2007-01-04	George Jackowski	Cene-E biopolymer marker indicative of age matched control
US7026129B2 (en) *	2001-11-23	2006-04-11	Syn X Pharma, Inc.	IG lambda biopolymer markers predictive of Alzheimers disease
WO2003046564A2 (en) *	2001-11-23	2003-06-05	Syn.X Pharma, Inc.	Protein biopolymer markers predictive of alzheimers disease
JP2005510723A (ja) *	2001-11-23	2005-04-21	シン．クスファーマ、インコーポレイテッド	年齢にマッチした対照を示すタンパク質バイオポリマーマーカー
US20030113808A1 (en) *	2001-12-13	2003-06-19	George Jackowski	Apolipoprotein biopolymer markers predictive of alzheimers disease
US20030119074A1 (en) *	2001-12-20	2003-06-26	George Jackowski	Diagnosis and treatment of dementia utilizing thrombospondin
CA2499843A1 (en) *	2002-09-25	2004-04-08	Genentech, Inc.	Novel compositions and methods for the treatment of psoriasis
WO2004089292A2 (en) *	2003-04-04	2004-10-21	The Regents Of The University Of California	Immunomodulatory agents for treatment of inflammatory diseases
FR2841787A1 (fr) *	2003-06-13	2004-01-09	Biomerieux Stelhys	Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
FR2841786A1 (fr) *	2003-06-13	2004-01-09	Biomerieux Stelhys	Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
FR2864086A1 (fr) *	2003-12-23	2005-06-24	Biomerieux Sa	Facteur cytotoxique isole associe a la sclerose en plaques et procede de detection dudit facteur cytotoxique
WO2006017647A1 (en)	2004-08-03	2006-02-16	Transtech Pharma, Inc.	Rage fusion proteins and methods of use
JP2008537143A (ja) *	2005-04-19	2008-09-11	バーミリオン，インコーポレイテッド	アルツハイマー病のためのバイオマーカーであるサポシンｄ及びｆａｍ３ｃ
RU2008116720A (ru)	2005-09-26	2009-11-10	Эвиджен, Инк. (Us)	Способы лечения наркозависимости и пагубных привычек в поведении
US7981424B2 (en)	2006-05-05	2011-07-19	Transtech Pharma, Inc.	RAGE fusion proteins, formulations, and methods of use thereof
EP2026804A1 (de)	2006-05-31	2009-02-25	Avigen, Inc.	Ibudilast zur hemmung der aktivität des makrophagen-migrationshemmungsfaktors
RU2513695C2 (ru)	2007-06-14	2014-04-20	Гэлэктика Фармасьютикалс, Инк.	Слитые белки rage
WO2009108840A1 (en) *	2008-02-27	2009-09-03	The Regents Of The University Of California	Yellow emitting phosphors based on ce3+-doped aluminate and via solid solution for solid-state lighting applications
US8173598B2 (en) *	2008-08-29	2012-05-08	The Board Of Trustees Of The University Of Illinois	Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway
WO2010035888A1 (ja) *	2008-09-25	2010-04-01	住友化学株式会社	マイクロドメイン病のバイオマーカー
CA2757079C (en)	2009-04-20	2015-05-19	Pfizer Inc.	Control of protein glycosylation and compositions and methods relating thereto
US9358273B2 (en)	2010-01-06	2016-06-07	The Texas A&M University System	Use of perlecan domain V in treating amyloidogenic disease
CA2804154C (en) *	2010-07-01	2021-06-01	The Texas A&M University System	Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function
JP5899213B2 (ja) *	2010-08-06	2016-04-06	マイカーティスエヌ．ヴェ．ＭｙＣａｒｔｉｓＮＶ	腎機能不全のバイオマーカーとしてのパールカン
WO2012157136A1 (ja) *	2011-05-19	2012-11-22	財団法人東京都医学総合研究所	リン酸化糖鎖を含有する組換えヒトサポシンｂタンパク質及びその用途
KR102119985B1 (ko)	2013-01-11	2020-06-05	마크 씨 허즈버그	ｍＲＮＡ 트랜스펙션을 수반하는 치료 조성물 및 방법
CN108780088A (zh) *	2015-11-06	2018-11-09	维蒂卡实验室公司	在伴侣动物中检测炎症标志物和治疗炎性病症的方法
US11253570B2 (en)	2016-11-07	2022-02-22	Medizinische Hochschule Hannover (Mhh)	S100A8/S100A9-induced immunotolerance in newborn subjects
EP3576732A1 (de) *	2017-01-31	2019-12-11	Medizinische Hochschule Hannover (MHH)	Natürliche verbindungen und fibrose
JP7216965B2 (ja) *	2017-02-21	2023-02-02	国立大学法人大阪大学	Ｓ１００ａ９を標的とする免疫原性組成物
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
JP7730841B2 (ja) *	2020-05-13	2025-08-28	ノルディックバイオサイエンスエー／エス	カルプロテクチンアッセイ
CN113336837B (zh) *	2021-07-21	2022-12-23	中国药科大学	多肽及其在制备抗神经退行性疾病药物方面的应用
TWI795872B (zh) *	2021-08-16	2023-03-11	微體生物醫學股份有限公司	抗gm2ap抗體及其應用
US11780917B2 (en)	2021-08-16	2023-10-10	Taiwan Innovative Integration Services Co., Ltd.	Anti-GM2AP antibody and applications thereof
WO2024012583A1 (zh) *	2022-07-14	2024-01-18	浩峰生物科技股份有限公司	人源化岩藻糖基化gm2ap抗体
US20240218078A1 (en) *	2022-12-07	2024-07-04	Vitae Biomedical Co., Ltd.	Anti-GM2AP ANTIBODY AND APPLICATIONS THEREOF
WO2024168151A2 (en) *	2023-02-09	2024-08-15	The Board Of Trustees Of The Leland Stanford Junior University	Capped peptides and methods for using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
WO1990007712A1 (de) *	1988-12-23	1990-07-12	Bissendorf Peptide Gmbh	Antigen, assoziiert mit degenerativen erscheinungen des zentralen nervensystems (zns), dagegen gerichtete antikörper sowie verfahren zur diagnose von dysfunktionen des zns
EP0465529B1 (de)	1989-03-21	1998-04-29	Vical, Inc.	Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en)	1992-08-28	1994-08-02	Life Technologies, Inc.	Cationic lipids
DE69434689D1 (de)	1993-06-10	2006-05-18	Genetic Therapy Inc	Adenovirale vektoren für die behandlung der hämophilie
KR960705798A (ko)	1993-11-24	1996-11-08	벤자민 에프 맥그로우	피페라진의 양쪽친화성 유도체(amphiphilic derivatives of piperazine)
FR2716198B1 (fr) *	1994-02-15	1996-04-19	Bio Merieux	Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.
FI955320L (fi)	1994-03-07	1995-11-24	Dow Chemical Co	Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
FR2719316B1 (fr)	1994-04-28	1996-05-31	Idm	Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
FR2722506B1 (fr)	1994-07-13	1996-08-14	Rhone Poulenc Rorer Sa	Composition contenant des acides nucleiques, preparation et utilisations
JPH08308582A (ja) *	1995-05-23	1996-11-26	Kao Corp	ラットｇｍ２アクチベータ蛋白質遺伝子
CA2222550A1 (en)	1995-06-07	1996-12-19	Baylor College Of Medicine	Nucleic acid transporters for delivery of nucleic acids into a cell
FR2745974B1 (fr) *	1996-03-14	1998-04-17		Animal modifie, utilisations et procede pour mesurer l'efficacite d'un procede therapeutique
EP0925504B1 (de) *	1996-09-12	2001-03-14	Bio Merieux	Verfahren zur detektion und/oder quantitativen bestimmung von einem gliotoxischen faktor
CA2214843A1 (en) *	1997-10-31	1999-04-30	Brigitte Rigat	A novel inhibitor of platelet activating factor

1999
- 1999-07-15 FR FR9909372A patent/FR2797402B1/fr not_active Expired - Fee Related
2000
- 2000-07-17 EP EP08172758A patent/EP2081028A1/de not_active Withdrawn
- 2000-07-17 AU AU65768/00A patent/AU6576800A/en not_active Abandoned
- 2000-07-17 AT AT00953247T patent/ATE419537T1/de not_active IP Right Cessation
- 2000-07-17 ES ES00953247T patent/ES2317845T3/es not_active Expired - Lifetime
- 2000-07-17 EP EP00953247A patent/EP1203239B1/de not_active Expired - Lifetime
- 2000-07-17 CA CA002379336A patent/CA2379336A1/fr not_active Abandoned
- 2000-07-17 US US10/030,937 patent/US7081345B1/en not_active Expired - Fee Related
- 2000-07-17 WO PCT/FR2000/002057 patent/WO2001005422A2/fr not_active Ceased
- 2000-07-17 DE DE60041265T patent/DE60041265D1/de not_active Expired - Lifetime
- 2000-07-17 JP JP2001510476A patent/JP2003509340A/ja active Pending
2006
- 2006-06-12 US US11/450,360 patent/US7510843B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60041265D1 (de)	2009-02-12
WO2001005422A2 (fr)	2001-01-25
EP1203239A2 (de)	2002-05-08
WO2001005422A3 (fr)	2002-02-28
US20060223121A1 (en)	2006-10-05
ES2317845T3 (es)	2009-05-01
EP1203239B1 (de)	2008-12-31
US7510843B2 (en)	2009-03-31
FR2797402A1 (fr)	2001-02-16
FR2797402B1 (fr)	2004-03-12
US7081345B1 (en)	2006-07-25
AU6576800A (en)	2001-02-05
CA2379336A1 (fr)	2001-01-25
JP2003509340A (ja)	2003-03-11
EP2081028A1 (de)	2009-07-22

Legal Events

Date	Code	Title	Description
2009-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE419537T1 (de)	2009-01-15	Verwendung eines polypeptids zur auffindung von multipler sklerose
RU95117238A (ru)	1997-07-20	Нуклеиновая кислота, рекомбинантная плазмида, рекомбинантный вектор, белок, синтетический пептид, химерная молекула, иммуногенная композиция, антисыворотка или антитела
CA2445421A1 (en)	2002-11-07	Von willebrand factor (vwf)-cleaving protease
McALEESE et al.	1988	Complete amino acid sequence of the neurone‐specific γ isozyme of enolase (NSE) from human brain and comparison with the non‐neuronal α form (NNE)
UA48105C2 (uk)	2002-08-15	ФРАГМЕНТ ДНК, ЯКИЙ КОДУЄ БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), РЕКОМБІНАНТНА МОЛЕКУЛА ДНК (ВАРІАНТИ), КЛІТИНА-ХАЗЯЇН (ВАРІАНТИ), СПОСІБ ОДЕРЖАННЯ БІЛКУ РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), БІЛОК РОДИНИ TGF-<font face="Symbol">b</font> (ВАРІАНТИ), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), АНТИТІЛО АБО ФРАГМЕНТ АНТИТІЛА (ВАРІАНТИ), МОЛЕКУЛА КДНК (ВАРІАНТИ)
DK1295944T3 (da)	2007-09-17	GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
EP0814158A3 (de)	1999-11-24	Abweichende Form des menschlichen C3a Rezeptor; diagnostzische und therapeutische Verwendungen
NO179412C (no)	1996-10-02	Hybrid DNA-molekyl som koder for fibronektinbindende protein, mikroorganismer inneholdende slike DNA-molekyler samt fremgangsmåte ved fremstilling av slikt protein
Goobes et al.	2007	Thermodynamic roles of basic amino acids in statherin recognition of hydroxyapatite
Sekiguchi et al.	2018	Basic fibroblast growth factor fused with tandem collagen‐binding domains from clostridium histolyticum collagenase ColG increases bone formation
ATE421531T1 (de)	2009-02-15	Apoptose-bezogene verbindungen und deren verwendung
HUP0100267A2 (hu)	2001-06-28	Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
WO1998006841A3 (en)	1998-05-07	Two human nsp-like proteins
JP2002517193A5 (de)	2006-07-27
EP0837130A3 (de)	1999-11-03	M Protein-Analog von Streptococcus pneumoniae
Blaber et al.	1987	A complete cDNA sequence for the major epidermal growth factor binding protein in the male mouse submandibular gland
WO1993017031A3 (en)	1993-12-23	Nucleic acids encoding dystrophin-associated proteins
EP1284297A3 (de)	2004-05-26	Identifizierung und Verwendung von Molekülen, welche mit Schmerz in Verbindung stehen
FR2726472B1 (fr)	1997-01-31	Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
EP0834568A3 (de)	1999-12-01	Speichel-bindendes Protein von Streptococcus pneumoniae
WO2003070768A3 (en)	2004-10-07	Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof
JP2005524387A5 (de)	2006-01-05
EP0887410A3 (de)	2000-12-13	DNA kodierend für ein Plasminogen aktivierendes Protein
JP2004533235A5 (de)	2006-01-05
NO178504C (no)	1996-04-10	Fr.måte for fr.stilling av minaktivin,DNA-molekyl,gen,vert,prober,preparat som omfatter prober,reagens for lokalisering og defini. av grenser for tumor i histologiske pröver,samt anvendelse av DNA-molekyl,minaktivin og preparat